Author

R.A. Soo

Observed name: RA. Soo

Institution: National University Cancer Institute, Singapore

Observed institutions: National University Cancer Institute, Singapore, National University Hospital

ORCID: 0000-0002-3053-3997

Observed ORCID: 0000-0002-3053-3997

OpenAlex ID: A5065632517

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study

2026 · A.T. Shaw, B.J. Solomon, et al. · Annals of Oncology · 21

1254MO Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab

2024 · A. Passaro, H.A. Yu, et al. · Annals of Oncology · 10

1398TiP Be6A Lung-01, a phase III study of sigvotatug vedotin (SV), an investigational antibody-drug conjugate (ADC) versus docetaxel in patients (pts) with previously treated non-small cell lung cancer (NSCLC)

2024 · S. Peters, C.M. De Cerqueira Mathias, et al. · Annals of Oncology · 6

6MO Zongertinib in treatment-naïve patients with HER2-mutant NSCLC, including those with active brain metastases: Beamion LUNG-1

2026 · J. Heymach, N. Yamamoto, et al. · ESMO Open · 1

MA08.02 Zipalertinib in NSCLC Patients (Pts) With EGFR Exon 20 Insertion (Ex20Ins) Mutations Who Received Prior Amivantamab

2025 · Z. Piotrowska, D. Nguyen, et al. · Journal of Thoracic Oncology · 1

269TiP A randomised phase III trial of adjuvant cemiplimab in patients with resected stage II-IIIA NSCLC who have not received prior adjuvant chemotherapy (ARCH)

2026 · R.A. Soo, A. Vervita, et al. · ESMO Open

281eTiP Lung cancer canvas: A global, real-world (RW) observational study assessing treatment patterns and outcomes in patients with early-stage non-small cell lung cancer (NSCLC)

2026 · G. Mountzios, R.A. Soo, et al. · ESMO Open

1086eP An observational study of afatinib 30mg daily in patients with advanced non-small cell lung cancer (NSCLC) harbouring common EGFR mutations

2025 · K. Sooi, P. Danchaivijitr, et al. · Annals of Oncology

1077eP Treatment outcomes and EGFR mutation profiles in stage IV NSCLC patients with brain metastases: Insights from a Singapore cohort

2025 · K.N. Tan, I. Loh, et al. · Annals of Oncology

974MO Efficacy of zipalertinib in Asian patients with EGFR exon 20 insertion mutated (Ex20ins) advanced non-small cell lung cancer (NSCLC)

2025 · R.A. Soo, V.H.F. Lee, et al. · Annals of Oncology

1029P A multi-centre, real-world study of treatment patterns and outcomes in Anaplastic Lymphoma Kinase (ALK)-rearranged non-small cell lung cancer: The Singapore experience

2025 · Y. Ang, Y.Y. Soon, et al. · Annals of Oncology

CO143 Clinical Outcomes of First-Line (1L) Treatments (Txs) in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (aNSCLC): A Systematic Literature Review (SLR)

2024 · M. Reck, RA. Soo, et al. · Value in Health

16MO Clinical impact of plasma EGFR analysis: Results from the ETOP-BOOSTER randomized phase II trial

2023 · R.A. Soo, U. Dafni, et al. · Journal of Thoracic Oncology

393MO Evaluating medical oncology outcomes (EMOO) in Asia study: Molecular testing, treatment patterns and outcome of patients with stage IV non-squamous non-small cell lung cancer

2022 · R. Stahel, L. Mery, et al. · Annals of Oncology

Works count: 14

Citation count: 39

H-index: 3

I10-index: 2